Cage-Free Repair Releases 2023 Cannabis Social Responsibility Report
TEMPLE CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Cage-Free Repair announced today that it…
Year: 2023
Cage-Free Repair Releases 2023 Cannabis Social Responsibility Report
TEMPLE CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Cage-Free Repair announced today that it…
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Gurnet Point Capital (“Gurnet Point”) and Novo…
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Gurnet Point Capital (“Gurnet Point”) and Novo…
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market…
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market…
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Genprex Inc. (NASDAQ: GNPX)…
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Genprex Inc. (NASDAQ: GNPX)…
Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia
Intelligent Bio Solutions at the 2023 Workplace Health & Safety Show Intelligent Bio Solutions at…
Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia
Intelligent Bio Solutions at the 2023 Workplace Health & Safety Show Intelligent Bio Solutions at…
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
– 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable…
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
– 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable…
Gradalis to Participate in the Cantor Global Healthcare Conference
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, clinical stage biotechnology…
Gradalis to Participate in the Cantor Global Healthcare Conference
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, clinical stage biotechnology…
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase…
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase…